- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
Beam Therapeutics Inc is a biotechnology business based in the US. Beam Therapeutics Inc shares (BEAM) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $29.01 – an increase of 3.87% over the previous week. Beam Therapeutics Inc employs 472 staff and has a trailing 12-month revenue of around $349.6 million.
Our top picks for where to buy Beam Therapeutics Inc stock
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%
How to buy Beam Therapeutics Inc stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – BEAM. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Beam Therapeutics Inc stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Beam Therapeutics Inc stock price (NASDAQ: BEAM)
Use our graph to track the performance of BEAM stocks over time.Beam Therapeutics Inc shares at a glance
Information last updated 2024-12-19.
| Latest market close | $29.01 |
|---|---|
| 52-week range | $20.84 - $49.50 |
| 50-day moving average | $25.43 |
| 200-day moving average | $26.13 |
| Wall St. target price | $49.20 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.58 |
Is it a good time to buy Beam Therapeutics Inc stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Beam Therapeutics Inc price performance over time
Historical closes compared with the close of $26.85 from 2024-12-19
| 1 week (2024-12-13) | -3.87% |
|---|---|
| 1 month (2024-11-21) | 13.87% |
| 3 months (2024-09-20) | 4.68% |
| 6 months (2024-06-21) | 17.04% |
| 1 year (2023-12-21) | -4.35% |
|---|---|
| 2 years (2022-12-21) | -37.89% |
| 3 years (2021-12-21) | 86.35 |
| 5 years (2019-12-17) | N/A |
Beam Therapeutics Inc financials
| Revenue TTM | $349.6 million |
|---|---|
| Gross profit TTM | $-250,674,000 |
| Return on assets TTM | -9.28% |
| Return on equity TTM | -18.29% |
| Profit margin | -41.07% |
| Book value | $9.97 |
| Market Capitalization | $2.2 billion |
TTM: trailing 12 months
Beam Therapeutics Inc share dividends
We're not expecting Beam Therapeutics Inc to pay a dividend over the next 12 months.
Beam Therapeutics Inc share price volatility
Over the last 12 months, Beam Therapeutics Inc's shares have ranged in value from as little as $20.84 up to $49.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Beam Therapeutics Inc's is 1.862. This would suggest that Beam Therapeutics Inc's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Beam Therapeutics Inc overview
Beam Therapeutics Inc. , a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc. , focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc. , for cardiovascular disease treatments; Sana Biotechnology, Inc. , to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease.
Frequently asked questions
What percentage of Beam Therapeutics Inc is owned by insiders or institutions?Currently 1.415% of Beam Therapeutics Inc shares are held by insiders and 93.088% by institutions. How many people work for Beam Therapeutics Inc?
Latest data suggests 472 work at Beam Therapeutics Inc. When does the fiscal year end for Beam Therapeutics Inc?
Beam Therapeutics Inc's fiscal year ends in December. Where is Beam Therapeutics Inc based?
Beam Therapeutics Inc's address is: 238 Main Street, Cambridge, MA, United States, 02142-1016 What is Beam Therapeutics Inc's ISIN number?
Beam Therapeutics Inc's international securities identification number is: US07373V1052
More resources on Finder
More guides on Finder
-
How to buy Merck-and-Company stock (MRK)
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
-
How to buy Eli Lilly and Company stock (LLY)
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
-
How to buy Intuitive Surgical stock (ISRG)
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
-
How to buy Vertex Pharmaceuticals stock (VRTX)
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
-
How to buy McKesson Corporation stock (MCK)
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
-
How to buy UnitedHealth Group Incorporated stock (UNH)
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
-
How to buy Amgen stock (AMGN)
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
-
How to buy Abbott Laboratories stock (ABT)
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
-
How to buy Pfizer stock (PFE)
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
-
How to buy Johnson & Johnson stock (JNJ)
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.
Ask a question